ArticleBMC musculoskeletal disorders2018

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.

Chi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.